Trials show that may improved survival and other clinical outcomes in patients in admitted severe disease
In clinical trials, a third of the participants received a second dose of<unk>  8 hours after the first dose if no clinical improvement was observed.
Tocilizumab
Idarucizumab
Sotrovimab
Sarilumab
Obiltoxaximab
Raxibacumab
Intravenous immunoglobulin
Rituximab